Literature DB >> 18027099

The effects of enrofloxacin on canine tendon cells and chondrocytes proliferation in vitro.

S Lim1, M A Hossain, J Park, S H Choi, G Kim.   

Abstract

Enrofloxacin, a fluoroquinolone antibiotic has been used widely in humans and domestic animals, including dogs, because of its broad-spectrum activity and relative safety. The side effects of fluoroquinolone, induced tendinopathy, tendonitis, spontaneous tendon rupture and cartilage damage, remain incompletely understood. In the present study, we investigated the in vitro effects of enrofloxacin on cell proliferation and induction of apoptosis in canine Achilles tendon cells and chondrocytes. Cell growth and proliferation after treating with enrofloxacin for 2-6 days was quantified by a colorimetric 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxyanilide inner salt (XTT) assay. The results showed that enrofloxacin could inhibit the proliferation of canine tendon cells and chondrocytes at increasing concentrations (10-200 microg/ml). The inhibition of proliferation of canine tendon cells and chondrocytes after exposure to enrofloxacin were associated with induction of apoptosis, as evidenced by the typical nuclear apoptotic condensed nuclei found using Hoechst 33258 staining. It was demonstrated that canine tendon cells and chondrocytes treated with 200 microg/ml enrofloxacin for 4 days exhibited apoptotic features and fragmentation of DNA. Enrofloxacin also increased the apoptosis of canine tendon cells and chondrocytes in a dose and time-dependent manner. The results indicate that enrofloxacin inhibits cell proliferation, induces apoptosis and DNA fragmentation, which might explain enrofloxacin-induced tendinopathy and cartilage damage.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18027099     DOI: 10.1007/s11259-007-9024-8

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.459


  30 in total

1.  Fluoroquinolones and risk of Achilles tendon disorders: case-control study.

Authors:  P D van der Linden; M C J M Sturkenboom; R M C Herings; H G M Leufkens; B H Ch Stricker
Journal:  BMJ       Date:  2002-06-01

2.  Ultrastructure of Achilles tendon from rats after treatment with fleroxacin.

Authors:  M Shakibaei; R Stahlmann
Journal:  Arch Toxicol       Date:  2001-04       Impact factor: 5.153

3.  Tendon disorders attributed to fluoroquinolones: a study on 42 spontaneous reports in the period 1988 to 1998.

Authors:  P D van der Linden; E P van Puijenbroek; J Feenstra; B A Veld; M C Sturkenboom; R M Herings; H G Leufkens; B H Stricker
Journal:  Arthritis Rheum       Date:  2001-06

4.  Characterization of fluoroquinolone-induced Achilles tendon toxicity in rats: comparison of toxicities of 10 fluoroquinolones and effects of anti-inflammatory compounds.

Authors:  Y Kashida; M Kato
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

5.  Chondrotoxicity of ciprofloxacin in immature beagle dogs: immunohistochemistry, electron microscopy and drug plasma concentrations.

Authors:  R Stahlmann; S Kühner; M Shakibaei; R Schwabe; J Flores; S A Evander; D C van Sickle
Journal:  Arch Toxicol       Date:  2000-01       Impact factor: 5.153

6.  In vitro dose-dependent effects of enrofloxacin on equine articular cartilage.

Authors:  L A Beluche; A L Bertone; D E Anderson; C W Kohn; S E Weisbrode
Journal:  Am J Vet Res       Date:  1999-05       Impact factor: 1.156

7.  Matrix metalloproteinase activities and their relationship with collagen remodelling in tendon pathology.

Authors:  Graham P Riley; Valerie Curry; Jeroen DeGroot; Benno van El; Nicole Verzijl; Brian L Hazleman; Ruud A Bank
Journal:  Matrix Biol       Date:  2002-03       Impact factor: 11.583

8.  Effects of enrofloxacin and ciprofloxacin hydrochloride on canine and equine chondrocytes in culture.

Authors:  M Egerbacher; J Edinger; W Tschulenk
Journal:  Am J Vet Res       Date:  2001-05       Impact factor: 1.156

9.  Epicondylitis after treatment with fluoroquinolone antibiotics.

Authors:  J C Le Huec; T Schaeverbeke; D Chauveaux; J Rivel; J Dehais; A Le Rebeller
Journal:  J Bone Joint Surg Br       Date:  1995-03

10.  Histological examination on Achilles tendon lesions induced by quinolone antibacterial agents in juvenile rats.

Authors:  M Kato; S Takada; Y Kashida; M Nomura
Journal:  Toxicol Pathol       Date:  1995 May-Jun       Impact factor: 1.902

View more
  6 in total

1.  Enrofloxacin enhances the effects of chemotherapy in canine osteosarcoma cells with mutant and wild-type p53.

Authors:  D York; S S Withers; K D Watson; K W Seo; R B Rebhun
Journal:  Vet Comp Oncol       Date:  2016-06-23       Impact factor: 2.613

2.  Deciphering the pathogenesis of tendinopathy: a three-stages process.

Authors:  Sai-Chuen Fu; Christer Rolf; Yau-Chuk Cheuk; Pauline Py Lui; Kai-Ming Chan
Journal:  Sports Med Arthrosc Rehabil Ther Technol       Date:  2010-12-13

3.  Determination of two fluoroquinolones and their combinations with hyaluronan effect in in vitro canine cartilage explants.

Authors:  Puntita Siengdee; Waranee Pradit; Siriwadee Chomdej; Korakot Nganvongpanit
Journal:  PeerJ       Date:  2019-03-12       Impact factor: 2.984

4.  Outpatient Clinical Trial in Dogs With Leptospirosis Treated With Enrofloxacin Hydrochloride-Dihydrate (ENRO-C).

Authors:  Lilia Gutierrez; Jesús Mendoza; Ana Bertha Rangel; Graciela Tapia; Maria Josefa Bernad; Hector Sumano
Journal:  Front Vet Sci       Date:  2019-10-15

Review 5.  Enrofloxacin-The Ruthless Killer of Eukaryotic Cells or the Last Hope in the Fight against Bacterial Infections?

Authors:  Łukasz Grabowski; Lidia Gaffke; Karolina Pierzynowska; Zuzanna Cyske; Marta Choszcz; Grzegorz Węgrzyn; Alicja Węgrzyn
Journal:  Int J Mol Sci       Date:  2022-03-26       Impact factor: 5.923

6.  Fluoroquinolone-mediated inhibition of cell growth, S-G2/M cell cycle arrest, and apoptosis in canine osteosarcoma cell lines.

Authors:  Kyoung won Seo; Roseline Holt; Yong-Sam Jung; Carlos O Rodriguez; Xinbin Chen; Robert B Rebhun
Journal:  PLoS One       Date:  2012-08-21       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.